Metabolic reprogramming in polycystic kidney disease explained by super-enhancers and CDK7: new therapeutic targets?
Crossref DOI link: https://doi.org/10.1038/s42255-020-0232-7
Published Online: 2020-07-13
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cassina, Laura
Boletta, Alessandra http://orcid.org/0000-0002-4704-4006
Text and Data Mining valid from 2020-07-13
Version of Record valid from 2020-07-13
Article History
First Online: 13 July 2020
Competing interests
: A.B. is a co-inventor on two patents for the targeting of cell metabolism in ADPKD.